Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

17, 2024 — Researchers discovered they could boost survival to 92% for patients ... Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed ...

Methotrexate-based regimens, even when radiation is deferred, prolong overall survival ... Hodgkin's lymphoma (NHL). Microscopically, PCNSL resembles systemic diffuse large B-cell lymphoma ...

Discover Qartemi, India's innovative CAR-T cell therapy for B-cell Non-Hodgkin Lymphoma, offering personalized and affordable ...

With each line of treatment, patients become more unresponsive to therapy, and it has a five-year survival rate of ... approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic ...

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...